Objective: To analyze the effect of intraperitoneal administration of paclitaxel combined with cisplatin in treatment of advanced ovarian cancer. Method: Fifty-four patients with advanced ovarian cancer in our hospital were randomly selected from the beginning of July 2018 to the end of June 2019. The principle of grouping was based on double-blind randomization method. In experimental group, 27 patients were given intraperitoneal administration of paclitaxel combined with cisplatin. In control group, 27 patients were given intravenous administration of paclitaxel combined with cisplatin. Clinical data of the two groups were compared. Results: Short-term clinical efficacy and T lymphocyte subsets of experimental group were significantly improved when compared with control group. The difference was significant (P<0.05). There was no significant difference in adverse reactions between the two groups (P>0.05). Conclusion: The effect of intraperitoneal administration of paclitaxel combined with cisplatin is ideal for treatment of advanced ovarian cancer patients.